Immedica UK Limited, formerly Diurnal Limited, is the British operating company behind Diurnal's endocrine medicines business. Incorporated in 2004 and historically based in Cardiff, it developed hydrocortisone treatments including Alkindi and Efmody for adrenal disorders. Neurocrine acquired the business in 2022, and Immedica acquired the group in January 2026; the operating company took its current legal name in February 2026.
| Also Known As | Neurocrine UK Limited |
|---|---|
| Revenue Type | revenue |
| Legal Name | Immedica UK Limited |
| Company Operating Status | Acquired |
| Full Address | Cardiff Medicentre, Heath Park, Cardiff, Wales CF14 4UJ, GB |
| Wellfound ID | diurnal |